 BioSpecifics Technologies Corp. NASDAQ: BSTC, a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX in North America, today announced the appointment of Joseph Truitt as Chief Executive Officer. Mr. Truitt was appointed interim Chief Executive Officer by the Companys Board of Directors on April 6, 2020 and assumed this permanent role on May 7, 2020. 